Defence Therapeutics Inc. (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Ryan Simms, PhD, as chief operating officer and head of radiopharmaceutical programs. The Canadian biotechnology company said Simms will oversee the development and operational planning of its radiopharmaceutical drug conjugate pipeline.
Simms brings more than 20 years of experience in targeted radiopharmaceutical development. His previous positions include leadership roles at Fusion Pharmaceuticals, Abdera Therapeutics and the Centre for Probe Development and Commercialization. At Fusion, he directed activities involving chemistry, radiochemistry, clinical manufacturing and external partnerships.
AstraZeneca completed its acquisition of Fusion in June 2024. The transaction included approximately US$2 billion in upfront consideration and a potential total value of approximately US$2.4 billion. Simms’ experience at Fusion provides relevant industry background, but it does not indicate that Defence’s earlier-stage programs will achieve comparable results.
Defence said Simms’ immediate responsibilities include choosing a lead radiopharmaceutical candidate, completing preclinical characterization and establishing the chemistry, manufacturing and controls framework needed for clinical development. Simms said the priority is to “select a lead candidate and move it systematically through preclinical characterization.”
The statement confirms that Defence has not yet selected its lead candidate. The company also did not announce new preclinical results, a regulatory submission or a clinical-trial timeline alongside the appointment.
Defence is developing its Accum precision drug-delivery platform for antibody-drug conjugates, radiopharmaceuticals and other biologic therapies. In January, the company expanded its collaboration with Canadian Nuclear Laboratories to support its radiopharmaceutical work. It also opened an office at McMaster Innovation Park in Hamilton, Ontario, in July.
Financial capacity remains a material consideration. Defence reported approximately C$8.95 million in cash and restricted cash as of March 31, 2026, including C$6 million classified as restricted. The company recorded no quarterly revenue and a net loss of approximately C$2.96 million.
The same filing stated that Defence did not have enough cash to finance its existing plans for at least 12 months and identified material uncertainty related to its ability to continue as a going concern. In March, the company raised approximately $9.6 million through 17.4 million units, with each unit containing one share and one warrant. Those securities create potential dilution for existing shareholders.
Upcoming Catalysts
The next operational milestones could include selection of a lead radiopharmaceutical candidate, preclinical data and details about manufacturing and isotope supply. Investors will also be watching for partnership activity, additional financing and a clearer regulatory timeline.
Sources
- Defence Therapeutics Appoints Ryan Simms as COO and Head of Radiopharmaceutical Programs — Newsfile, August 17, 2026
- Defence Therapeutics Quarterly Listing Statement and Financial Results — CSE, June 3, 2026
- Defence Therapeutics Closes $9.6 Million Private Placement — Newsfile, March 9, 2026
- Defence Therapeutics Opens McMaster Innovation Park Office — Newsfile, July 8, 2026
- AstraZeneca Completes Acquisition of Fusion Pharmaceuticals — AstraZeneca, June 4, 2024
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, securities-exchange filings and publicly available corporate sources. Securities discussed or referenced include Defence Therapeutics Inc. (CSE: DTC; OTCQB: DTCFF; FSE: DTC). Biotech Stocks Daily has not received compensation from any company mentioned, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include Defence Therapeutics’ August 17, 2026 leadership announcement, its June 3, 2026 CSE quarterly filing, its March 9, 2026 financing announcement, its July 8, 2026 Hamilton office announcement and AstraZeneca’s June 4, 2024 acquisition announcement. Most information concerning Defence’s programs and development plans originated from the company and has not been independently validated by Biotech Stocks Daily.
The appointment of an executive does not constitute clinical, scientific or regulatory progress. Defence has not selected a lead radiopharmaceutical candidate, and its programs remain subject to preclinical testing, manufacturing development, regulatory review and financing availability. There is no assurance that any candidate will enter clinical trials or receive regulatory approval.
Financial information reflects Defence’s position as of March 31, 2026 and is reported in Canadian dollars unless otherwise noted. The company reported no revenue, ongoing operating losses and material uncertainty related to its ability to continue as a going concern. Its recent financing involved shares and warrants that may dilute existing shareholders.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
